The gut-brain axis: The role of melatonin in linking psychiatric, inflammatory and neurodegenerative conditions

Advances in Integrative Medicine

Volumn 2, Issue 1, 2015, Pages 31-37

  Anderson, George ^a   Maes, Michael ^b  

^a Davies Court ^*  (United Kingdom)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

Depression; Gut permeability; Inflammasome; Inflammation; Melatonin; Oxidative and nitrosative stress

Indexed keywords

MELATONIN;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DEPRESSION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; PARKINSON DISEASE; PERMEABILITY; PRIORITY JOURNAL; PSYCHIATRY; SCHIZOPHRENIA;

EID: 85013894595     PISSN: 22129588     EISSN: 22129596     Source Type: Journal    
DOI: 10.1016/j.aimed.2014.12.007     Document Type: Article

References (117)

1. Anderson G., Maes M. Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. Curr Pharm Des 2014, 20(23):3812-3847.
2. Anderson G., Maes M. Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol Disord Drug Targets 2014, 13(5):817-827.
3. Mariadason J.M., Catto-Smith A., Gibson P.R. Modulation of distal colonic epithelial barrier function by dietary fibre in normal rats. Gut 1999, 44(March (3)):394-399.
4. Sommansson A., Saudi W.S., Nylander O., Sjöblom M. Melatonin inhibits alcohol-induced increases in duodenal mucosal permeability in rats in vivo. Am J Physiol Gastrointest Liver Physiol 2013, 305(July (1)):G95-G105.
5. da Silva S.T., dos Santos C.A., Bressan J. Intestinal microbiota relevance to obesity and modulation by prebiotics and probiotics. Nutr Hosp 2013, 28(July-August (4)):1039-1048.
6. Vanuytsel T., van Wanrooy S., Vanheel H., Vanormelingen C., Verschueren S., Houben E., et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014, 63(August (8)):1293-1299.
7. Moreira A.P., Texeira T.F., Ferreira A.B., Peluzio Mdo C., Alfenas Rde C. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 2012, 108(September (5)):801-809.
8. Sommansson A., Nylander O., Sjöblom M. Melatonin decreases duodenal epithelial paracellular permeability via a nicotinic receptor-dependent pathway in rats in vivo. J Pineal Res 2013, 54(April (3)):282-291.
9. Bala S., Marcos M., Gattu A., Catalano D., Szabo G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLOS ONE 2014, 9(May (5)):e96864.
10. Xiao S., Fei N., Pang X., Shen J., Wang L., Zhang B., et al. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol 2014, 87(February (2)):357-367.
11. Dotson V.M., Beydoun M.A., Zonderman A.B. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010, 75(July (1)):27-34.
12. Wiest R. Bacterial translocation. Biosci Microflora 2005, 24:61-90.
13. Maes M., Leunis J.C. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro Endocrinol Lett 2008, 29(December (6)):902-910.
14. Maes M., Kubera M., Leunis J.C., Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord 2012, 141:55-62.
15. Lin W.N., Lin C.C., Cheng H.Y., Yang C.M. Regulation of cyclooxygenase-2 and cytosolic phospholipase A2 gene expression by lipopolysaccharide through the RNA-binding protein HuR: involvement of NADPH oxidase, reactive oxygen species and mitogen-activated protein kinases. Br J Pharmacol 2011, 163:1691-1706.
16. Feng L., Xia Y., Garcia G.E., Hwang D., Wilson C.B. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 1995, 95:1669-1675.
17. Berg R.D., Garlington A.W. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979, 23:403-411.
18. Wiest R., Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005, 41:422-433.
19. Check J., Byrd C.L., Menio J., Rippe R.A., Hines I.N., Wheeler M.D. Src kinase participates in LPS-induced activation of NADPH oxidase. Mol Immunol 2010, 47:756-762.
20. 2- and lysozyme from human monocytes in vitro. Indian J Exp Biol 1991, 29:910-915.
21. Maes M., Mihaylova I., Kubera M., Leunis J.C., Geffard M. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 2011, 135:414-418.
22. Moylan S., Maes M., Wray N.R., Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2012, 18:595-606.
23. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36:764-785.
24. Maes M., Ringel K., Kubera M., Anderson G., Morris G., Galecki P., et al. In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. J Affect Disord 2013, 150(September (2)):223-230.
25. Anderson G., Maes M. Metabolic syndrome, Alzheimer's, schizophrenia and depression: role for leptin, melatonin, kynurenine pathways and neuropeptides. Metabolic syndrome and neurological disorders 2013, John Wiley & Sons Ltd., Chichester, UK, [chapter 13]. T. Farooqui, A.A. Farooqui (Eds.).
26. Stander V.A., Thomsen C.J., Highfill-McRoy R.M. Etiology of depression comorbidity in combat-related PTSD: a review of the literature. Clin Psychol Rev 2014, 34(March (2)):87-98.
27. Berk M., Berk L., Dodd S., Cotton S., Macneil C., Daglas R., et al. Stage managing bipolar disorder. Bipolar Disord 2014, 16(August (5)):471-477.
28. Severance E.G., Yolken R.H., Eaton W.W. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr Res 2015, [in press].
29. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995, 29:141-152.
30. Maes M., Delange J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997, 66:1-11.
31. Rapaport M.H. Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord 1994, 32:149-156.
32. Modabbernia A., Taslimi S., Brietzke E., Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013, 74(July (1)):15-25.
33. Anderson G., Maes M. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 2013, April (42):5-19.
34. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70(October (7)):663-671.
35. Oganesyan L.P., Mkrtchyan G.M., Sukiasyan S.H., Boyajyan A.S. Classic and alternative complement cascades in post-traumatic stress disorder. Bull Exp Biol Med 2009, 148(December (6)):859-861.
36. Newton T.L., Fernandez-Botran R., Miller J.J., Burns V.E. Interleukin-6 and soluble interleukin-6 receptor levels in posttraumatic stress disorder: associations with lifetime diagnostic status and psychological context. Biol Psychol 2014, May (99):150-159.
37. Gill J., Vythilingam M., Page G.G. Low cortisol, high DHEA, and high levels of stimulated TNF-alpha, and IL-6 in women with PTSD. J Trauma Stress 2008, 21(December (6)):530-539.
38. Maes M., Lin A.H., Delmeire L., Van Gastel A., Kenis G., De Jongh R., et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999, 45:833-839.
39. Stam R., Akkermans L.M., Wiegant V.M. Trauma and the gut: interactions between stressful experience and intestinal function. Gut 1997, 40(June (6)):704-709.
40. Tillisch K. The effects of gut microbiota on CNS function in humans. Gut Microbes 2014, 5(May (3)).
41. Severance E.G., Gressitt K.L., Stallings C.R., Origoni A.E., Khushalani S., Leweke F.M., et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res 2013, 148(August (1-3)):130-137.
42. Xu Q., Anderson D., Lurie-Beck J. The relationship between abdominal obesity and depression in the general population: a systematic review and meta-analysis. Obes Res Clin Pract 2011, 5(October-December (4)):e267-e360.
43. Wiltink J., Michal M., Wild P.S., Schneider A., König J., Blettner M., et al. Associations between depression and diabetes in the community: do symptom dimensions matter? Results from the Gutenberg Health Study. PLOS ONE 2014, 9(August (8)):e105499.
44. Ren Y., Yang H., Browning C., Thomas S., Liu M. Prevalence of depression in coronary heart disease in China: a systematic review and meta-analysis. Chin Med J (Engl) 2014, 127(August (16)):2991-2998.
45. Janssen D.J., Müllerova H., Agusti A., Yates J.C., Tal-Singer R., Rennard S., et al. Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. Respir Med 2014, 108(11):1647-1654.
46. Youssef N.A., Abdelmalek M.F., Binks M., Guy C.D., Omenetti A., Smith A.D., et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int 2013, 33(August (7)):1062-1070.
47. Watts S., Leydon G., Birch B., Prescott P., Lai L., Eardley S., et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 2014, 4(March (3)):003901.
48. Yang Y.L., Liu L., Wang Y., Huang D.S., Wang S.M., Wang L. The prevalence of depression and anxiety among Chinese adults with cancer: a systematic review and meta-analysis. BMC Cancer 2013, 13(August):393.
49. Duseja A., Chawla Y.K. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis 2014, 18(February (1)):59-71.
50. Moreno-Indias I., Cardona F., Tinahones F.J., Queipo-Ortuño M.I. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol 2014, 5(April):190.
51. Tilg H., Moschen A.R. Microbiota and diabetes: an evolving relationship. Gut 2014, 63(September (9)):1513-1521.
52. Ohtani N., Yoshimoto S., Hara E. Obesity and cancer: a gut microbial connection. Cancer Res 2014, 74(April (7)):1885-1889.
53. Stock J. Gut microbiota: an environmental risk factor for cardiovascular disease. Atherosclerosis 2013, 229(August (2)):440-442.
54. Han M.K., Huang Y.J., Lipuma J.J., Boushey H.A., Boucher R.C., Cookson W.O., et al. Significance of the microbiome in obstructive lung disease. Thorax 2012, 67(May (5)):456-463.
55. Visschers R.G., Luyer M.D., Schaap F.G., Olde Damink S.W., Soeters P.B. The gut-liver axis. Curr Opin Clin Nutr Metab Care 2013, 16(September (5)):576-581.
56. Dhikav V., Sethi M., Anand K.S. Medial temporal lobe atrophy in Alzheimer's disease/mild cognitive impairment with depression. Br J Radiol 2014, (July):20140150.
57. Lawrence B.J., Gasson N., Kane R., Bucks R.S., Loftus A.M. Activities of daily living, depression, and quality of life in Parkinson's disease. PLOS ONE 2014, 9(July (7)):e102294.
58. Feinstein A., Magalhaes S., Richard J.F., Audet B., Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol 2014, 10(9):507-517.
59. Kiloh L.G. Depressive illness masquerading as dementia in the elderly. Med J Aust 1981, 2(November (10)):550-553.
60. Anderson G., Maes M. TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease. CNS Neurol Disord Drug Targets 2014, 13(February (1)):137-149.
61. Tan L., Yu J.T., Tan L. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci 2012, 323(December (1/2)):1-8.
62. Anderson G., Rodriguez M. Multiple sclerosis, seizures, and antiepileptics: role of IL-18, IDO, and melatonin. Eur J Neurol 2011, 18(May (5)):680-685.
63. Anderson G., Ojalla J. Alzheimer's and seizures: interleukin-18, indoleamine 2,3-dioxygenase and quinolinic acid. Int J Trytophan Res 2010, 3:169-173.
64. Forsyth C.B., Shannon K.M., Kordower J.H., Voigt R.M., Shaikh M., Jaglin J.A., et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS ONE 2011, 6(12):e28032.
65. Telesford K., Ochoa-Repáraz J., Kasper L.H. Gut commensalism, cytokines, and central nervous system demyelination. J Interferon Cytokine Res 2014, 34(August (8)):605-614.
66. Berer K., Mues M., Koutrolos M., Rasbi Z.A., Boziki M., Johner C., et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011, 479(October (7374)):538-541.
67. Carmeli C., Donati A., Antille V., Viceic D., Ghika J., von Gunten A., et al. Demyelination in mild cognitive impairment suggests progression path to Alzheimer's disease. PLoS ONE 2013, 8(August (8)):e72759.
68. Pérez Martínez G., Bäuerl C., Collado M.C. Understanding gut microbiota in elderly's health will enable intervention through probiotics. Benef Microbes 2014, 5(September (3)):235-246.
69. Maes M., Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatr Res 2012, 196(23):243-249.
70. Tan D.X., Manchester L.C., Liu X., Rosales-Corral S.A., Acuna-Castroviejo D., Reiter R.J. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin's primary function and evolution in eukaryotes. J Pineal Res 2013, 54:127-138.
71. Anderson G., Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Br Dis 2012, 27(2):113-119.
72. Peter-Derex L., Yammine P., Bastuji H., Croisile B. Sleep and Alzheimer's disease. Sleep Med Rev 2015, 19C:29-38.
73. Melatonin and melatonergic drugs in clinical practice 2014, Springer. V. Srinivasan, S.D. Shillcott, S. Oter, A. Brzezinski (Eds.).
74. Hansen M.V., Danielsen A.K., Hageman I., Rosenberg J., Gögenur I. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2014, 24(11):1719-1728.
75. da Silveira Cruz-Machado S., Pinato L., Tamura E.K., Carvalho-Sousa C.E., Markus R.P. Glia-pinealocyte network: the paracrine modulation of melatonin synthesis by tumor necrosis factor (TNF). PLoS ONE 2012, 7(7):e40142.
76. Pontes G.N., Cardoso E.C., Carneiro-Sampaio M.M., Markus R.P. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppress nocturnal melatonin production. J Pineal Res 2007, 43:365-371.
77. Lardone P.J., Carrillo-Vico A., Naranjo M.C., De Felipe B., Vallejo A., Karasek M., et al. Melatonin synthesized by Jurkat human leukemic T cell line is implicated in IL-2 production. J Cell Physiol 2006, 206:273-279.
78. Carrillo-Vico A., Lardone P.J., Alvarez-Sánchez N., Rodríguez-Rodríguez A., Guerrero J.M. Melatonin: buffering the immune system. Int J Mol Sci 2013, 14(April (4)):8638-8683.
79. Calvo J.R., González-Yanes C., Maldonado M.D. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res 2013, 55(September (2)):103-120.
80. Hriscu M., Saulea G., Ostriceanu S., Baciu I. Circadian phagocytic activity in rats under light-dark and constant light regimens. Rom J Physiol 2002-2003, 39-40:17-26.
81. Markus R.P., Cecon E., Pires-Lapa M.A. Immune-pineal axis: nuclear factor κB (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells. Int J Mol Sci 2013, 14(May (6)):10979-10997.
82. Muxel S.M., Pires-Lapa M.A., Monteiro A.W.A., Cecon E., Tamura E.K., Floeter-Winter L.M., et al. NF-κB drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-N-acetyltransferase (AA-NAT) gene. PLoS ONE 2012, 7(12):e52010.
83. Liu Y.J., Zhuang J., Zhu H.Y., Shen Y.X., Tan Z.L., Zhou J.N. Cultured rat cortical astrocytesynthesize melatonin: absence of a diurnal rhythm. J Pineal Res 2007, 43(3):232-238.
84. Sharma R., Ottenhof T., Rzeczkowska P.A., Niles L.P. Epigenetic targets for melatonin: induction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. J Pineal Res 2008, 45(3):277-284.
85. Joyner A.H., Roddey J.C., Bloss C.S., Bakken T.E., Rimol L.M., Melle I., et al. A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations. Proc Natl Acad Sci U S A 2009, 106(36):15483-15488.
86. Gantz S.C., Ford C.P., Neve K.A., Williams J.T. Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathway. J Neurosci 2011, 31(35):12629-12637.
87. Piton A., Gauthier J., Hamdan F.F., Lafrenière R.G., Yang Y., Henrion E., et al. Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Mol Psychiatry 2011, 16(8):867-880.
88. Didier N., Romero I.A., Créminon C., Wijkhuisen A., Grassi J., Mabondzo A. Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J Neurochem 2003, 86(1):246-254.
89. Argaw A.T., Asp L., Zhang J., Navrazhina K., Pham T., Mariani J.N., et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 2012, 122(7):2454-2568.
90. Markus R.P., Silva C.L., Franco D.G., Barbosa E.M., Ferreira Z.S. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs?. Pharmacol Ther 2010, 126(3):251-262.
91. Lu B., Kwan K., Levine Y.A., Olofsson P.S., Yang H., Li J., et al. Alpha 7 nicotinic acetylcholine receptor signaling inhibits inflammasome activation by preventing mitochondrial DNA release. Mol Med 2014, 20:350-358.
92. Liu Y., Hu J., Wu J., Zhu C., Hui Y., Han Y., et al. α7 nicotinic acetylcholine receptormediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation. J Neuroinflamm 2012, 9:98.
93. Mishra N.C., Rirsimaah J., Boyd R.T., Singh S.P., Gundavarapu S., Langley R.J., et al. Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha9/alpha 10-nicotinic receptors. J Immunol 2010, 185(1):588-596.
94. Bubenik G.A., Brown G.M., Grota L.J. Immunohistological localization of melatonin in the rat digestive system. Experientia 1977, 33:662-663.
95. Bubenik G.A., Pang S.F., Hacker R.R., Smith P.S. Melatonin concentrations in serum and tissues of porcine gastrointestinal tract and their relationship to the intake and passage of food. J Pineal Res 1996, 21:251-256.
96. Bertrand P.P., Polglaze K.E., Bertrand R.L., Sandow S.L., Pozo M.J. Detection of melatonin production from the intestinal epithelium using electrochemical methods. Curr Pharm Des 2014, 20(30):4802-4806.
97. Sun X., Shao Y., Jin Y., Huai J., Zhou Q., Huang Z., et al. Melatonin reduces bacterial translocation by preventing damage to the intestinal mucosa in an experimental severe acute pancreatitis rat model. Exp Ther Med 2013, 6(December (6)):1343-1349.
98. Siah K.T., Wong R.K., Ho K.Y. Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol 2014, 20(March (10)):2492-2498.
99. Eliasson L. Melatonin heals the gut. Acta Physiol (Oxf) 2014, 212(2):120-121.
100. Glenister R., McDaniel K., Francis H., Venter J., Jensen K., Dusio G., et al. Therapeutic actions of melatonin on gastrointestinal cancer development and progression. Transl Gastrointest Cancer 2013, 2(January (1)).
101. Wikoff W.R., Anfora A.T., Liu J., Schultz P.G., Lesley S.A., Peters E.C., Siuzdak G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 2009, 106(March (10)):3698-3703.
102. Zambetti L.P., Mortellaro A. NLRPs, microbiota, and gut homeostasis: unravelling the connection. J Pathol 2014, 233(August (4)):321-330.
103. Xiao Y.T., Li G.X., Wang X.M. Effect mechanism of NOD like receptor signaling pathway on intestinal mucosal barrier of rat during early phase of acute intra-abdominal infection. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013, 25(September (9)):527-532.
104. Sun Y., Zhang M., Chen C.C., Gillilland M., Sun X., El-Zaatari M., et al. Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 2013, 144(June (7)):1478-1487. 1487.e1-8.
105. Kim T.H., Kim S.J., Lee S.M. Stimulation of the α7 nicotinic acetylcholine receptor protects against sepsis by inhibiting Toll-like receptor via phosphoinositide 3-kinase activation. J Infect Dis 2014, 209(May (10)):1668-1677.
106. Galley H.F., Lowes D.A., Allen L., Cameron G., Aucott L.S., Webster N.R. Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. J Pineal Res 2014, 56(May (4)):427-438.
107. Shimada K., Crother T.R., Karlin J., Dagvadorj J., Chiba N., Chen S., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012, 36(March (3)):401-414.
108. She F., Wang W., Wang Y., Tang P., Wei J., Chen H., et al. Melatonin protects MG63 osteoblast-like cells from hydrogen peroxide-induced cytotoxicity by maintaining mitochondrial function. Mol Med Rep 2014, 9(February (2)):493-498.
109. Haastrup E., Bukh J.D., Bock C., Vinberg M., Thorner L.W., Hansen T., et al. Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. J Affect Disord 2012, 136(January (1/2)):134-138.
110. Liu L., Chan C. The role of inflammasome in Alzheimer's disease. Ageing Res Rev 2014, 15(May):6-15.
111. Zhang Y., Liu L., Peng Y.L., Liu Y.Z., Wu T.Y., Shen X.L., et al. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci Ther 2014, 20(February (2)):119-124.
112. Alamili M., Klein M., Lykkesfeldt J., Rosenberg J., Gögenur I. Circadian variation in the response to experimental endotoxemia and modulatory effects of exogenous melatonin. Chronobiol Int 2013, 30(November (9)):1174-1180.
113. Stahl S.M. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectr 2014, 19(June (3)):207-212.
114. Mawe G.M., Hoffman J.M. Serotonin signalling in the gut - functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol 2013, 10(August (8)):473-486.
115. Mayer E.A., Savidge T., Shulman R.J. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014, 146(May (6)):1500-1512.
116. Cryan J.F., Dinan T.G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012, 13(October (10)):701-712.
117. Farmer A.D., Randall H.A., Aziz Q. It's a gut feeling: how the gut microbiota affects the state of mind. J Physiol 2014, 592(July (Pt 14)):2981-2988.